Last updated on November 2017

EMR200147-501 Title A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects with HIV-Associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for injection) to a Similar Group of Subjects not Exposed to EGRIFTA®


Brief description of study

EMR200147-501 Title A Phase 4, Observational, Multicenter, 10-year Prospective Cohort Safety Study Comparing Subjects with HIV-Associated Abdominal Lipohypertrophy Exposed to EGRIFTA® (Tesamorelin for injection) to a Similar Group of Subjects not Exposed to EGRIFTA®

Detailed Study Description

The primary objective of the study is to evaluate the longterm effect of EGRIFTA®, 2 mg once daily subcutaneously (SC), on the development of malignancies in subjects with human immunodeficiency virus (HIV) infection and concomitant abdominal lipohypertrophy.

ClinicalTrials.gov Identifier: NCT01579695

Clinical Study Identifier: TX6021

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Crystal Nagle

Reading Hospital Clinical Trials Office
West Reading, PA USA
  Connect »